X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

19 окт 2021 08:00:02 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

04 окт 2021 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

15 сен 2021 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Promotes Mary DiBiase, Ph.D. to Chief Operating Officer

08 сен 2021 08:00:04 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 сен 2021 16:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

01 сен 2021 08:00:03 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate at Canaccord Genuity’s Virtual 41st Annual Growth Conference

04 авг 2021 16:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results

03 авг 2021 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021

22 июл 2021 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 июл 2021 16:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

11 июн 2021 03:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia

26 май 2021 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences

17 май 2021 08:00:02 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

12 май 2021 10:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

06 май 2021 08:00:02 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 май 2021 16:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

22 апр 2021 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

07 апр 2021 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 апр 2021 16:05:00 Источник Nasdaq GlobeNewswire